Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$51.70 USD
+2.37 (4.80%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $51.71 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Income Statements
Fiscal Year end for Corbus Pharmaceuticals Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 1 | 4 | 36 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 1 | 4 | 36 |
Selling & Adminstrative & Depr. & Amort Expenses | 45 | 40 | 57 | 127 | 113 |
Income After Depreciation & Amortization | -45 | -40 | -56 | -123 | -77 |
Non-Operating Income | 3 | 0 | 12 | 12 | 6 |
Interest Expense | 3 | 2 | 2 | 0 | 0 |
Pretax Income | -45 | -42 | -46 | -111 | -71 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -45 | -42 | -46 | -111 | -71 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -45 | -42 | -46 | -111 | -71 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -44 | -37 | -53 | -121 | -76 |
Depreciation & Amortization (Cash Flow) | 1 | 2 | 3 | 2 | 1 |
Income After Depreciation & Amortization | -45 | -40 | -56 | -123 | -77 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.33 | 4.17 | 4.10 | 2.60 | 2.13 |
Diluted EPS Before Non-Recurring Items | -10.31 | -8.95 | -11.11 | -42.64 | -33.63 |
Diluted Net EPS (GAAP) | -10.31 | -10.15 | -11.11 | -42.64 | -33.63 |
Fiscal Year end for Corbus Pharmaceuticals Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 10.99 | 9.62 | 10.10 | 9.49 | 8.19 |
Income After SG&A, R&D, and Dept/Amort Expenses | -10.99 | -9.62 | -10.10 | -9.49 | -8.19 |
Non-Operating Income | 1.64 | 2.90 | 2.79 | 0.20 | 0.18 |
Interest Expense | 0.65 | 0.18 | 1.39 | 0.76 | 0.78 |
Pretax Income | -10.00 | -6.90 | -8.02 | -10.05 | -8.78 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -10.00 | -6.90 | -8.02 | -10.05 | -8.78 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -10.00 | -6.90 | -8.02 | -10.05 | -8.78 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 11.05 | 8.31 | 4.42 | 4.42 | 4.28 |
Diluted EPS Before Non-Recurring Items | -0.90 | -0.83 | -1.81 | -2.27 | -2.05 |
Diluted Net EPS (GAAP) | -0.90 | -0.83 | -1.75 | -2.27 | -2.05 |